Pfizer appeals Hors-List decision of ComCo

On December 1, 2009, the ComCo published its decision according to which it is unlawful to issue price recommendations for hors-list pharmaceuticals (i.e. pharmaceuticals that are not price regulated). Pfizer decided to appeal this decision.

Lenz & Staehelin (Marcel Meinhardt and Daniel Hufschmid) advises Pfizer in the appeal.